Biotech & Medical Venture Deals Roundup
by Adam Rubenstein
NovaVision (Boca Raton, FL) a non-invasive device that may restore vision loss in stroke and traumatic brain injury patients has raised $20M in Series C. The deal was led by Chicago Growth Partners and included Johnson & Johnson Development Corp., Oakwood Medical Investors, Tullis-Dickerson, Noro-Moseley Partners, Crossbow Ventures.
Juvaris BioTherapeutics (Pleasanton, CA) an oncology and anti-infective vaccine platform technology closed on $6M of a $12M Series A led by Kleiner Perkins.
Fluidigm Corporation (San Francisco) a producer of integrated fluidic circuits for the life sciences raised $37M in a Series E financing. The round was lead by Cross Creek Capital the private equity affiliate of Wasatch Advisors, Inc
Pacific Biosciences (Menlo Park, CA) a company focused on DNA gene sequencing, has raised approximately $50M in Series D funding. The financing was led by Maverick Capital and included by return backers Alloy Ventures, Kleiner Perkins and Mohr Davidow Ventures.
InteKrin Therapeutics (Palo Alto, CA) a clinical stage biopharmaceutical company focused on products for diabetes, metabolism and obesity has secured $23M in Series B funding. The financing was led by Sofinnova Ventures and included Orbimed Advisors, Vivo Ventures, and return backer Sears Capital Management.
Sequoia Pharmaceuticals (Gaithersburg, MD) drug developer focused on the treatment of drug-resistant HIV infections, has raised $35M in Series C funding. The deal was led by Wellcome Trust and existing investors Healthcare Ventures, Sofinnova Partners and Aberdare Ventures. The round was also joined by MedImmune Ventures.
Semafore Pharmaceuticals (Indianapolis, IN) a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway has raised $9.5M in Series B funding led by Twilight Venture Partners.
Proprius Pharmaceuticals (San Diego, CA) a drug developer focused on rheumatology and autoimmune diseases, has raised $11M in Series A funding led by Atlas Venture and joined by Forward Ventures, CDIB BioScience Venture Management along with return backers Fog City Fund and Windamere Venture Partners.
Horizon Therapeutics (Palo Alto, CA) a late stage biopharmaceutical company focused on development of drugs for pain relief has raised $15M in Series B funding. The deal was lead by Scale Venture Partners, and joined by return backers Sutter Hill Ventures and Pequot Ventures.
Variation Biotechnologies (Ottawa, Canada) a maker of vaccines for infectious diseases, has raised US$35.7M in Series A funding. The deal was lead by Clarus Ventures with participation from Arch Venture Partners and 5AM Ventures.
SunTen Phytotech (Taipei, Taiwan) a botanical drug development company, has raised $10M in Series B funding led by PacLink Capital, Taiwan Global Biofund Venture and 3V SourceOne Venture Capital.
Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised another $11.2M in Series B funding. Participants include Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures, Triathlon Medical Ventures and Guidant Compass Group.
Conatus Pharmaceuticals (San Diego, CA) a drug developer focused on liver disease, has secured $6.62 million of a $27.37M Series A round. Participants include Aberdare Ventures, Bay City Capital, Advent International and Hale BioPharma Ventures.
____________________
NovaVision (Boca Raton, FL) a non-invasive device that may restore vision loss in stroke and traumatic brain injury patients has raised $20M in Series C. The deal was led by Chicago Growth Partners and included Johnson & Johnson Development Corp., Oakwood Medical Investors, Tullis-Dickerson, Noro-Moseley Partners, Crossbow Ventures.
Juvaris BioTherapeutics (Pleasanton, CA) an oncology and anti-infective vaccine platform technology closed on $6M of a $12M Series A led by Kleiner Perkins.
Fluidigm Corporation (San Francisco) a producer of integrated fluidic circuits for the life sciences raised $37M in a Series E financing. The round was lead by Cross Creek Capital the private equity affiliate of Wasatch Advisors, Inc
Pacific Biosciences (Menlo Park, CA) a company focused on DNA gene sequencing, has raised approximately $50M in Series D funding. The financing was led by Maverick Capital and included by return backers Alloy Ventures, Kleiner Perkins and Mohr Davidow Ventures.
InteKrin Therapeutics (Palo Alto, CA) a clinical stage biopharmaceutical company focused on products for diabetes, metabolism and obesity has secured $23M in Series B funding. The financing was led by Sofinnova Ventures and included Orbimed Advisors, Vivo Ventures, and return backer Sears Capital Management.
Sequoia Pharmaceuticals (Gaithersburg, MD) drug developer focused on the treatment of drug-resistant HIV infections, has raised $35M in Series C funding. The deal was led by Wellcome Trust and existing investors Healthcare Ventures, Sofinnova Partners and Aberdare Ventures. The round was also joined by MedImmune Ventures.
Semafore Pharmaceuticals (Indianapolis, IN) a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway has raised $9.5M in Series B funding led by Twilight Venture Partners.
Proprius Pharmaceuticals (San Diego, CA) a drug developer focused on rheumatology and autoimmune diseases, has raised $11M in Series A funding led by Atlas Venture and joined by Forward Ventures, CDIB BioScience Venture Management along with return backers Fog City Fund and Windamere Venture Partners.
Horizon Therapeutics (Palo Alto, CA) a late stage biopharmaceutical company focused on development of drugs for pain relief has raised $15M in Series B funding. The deal was lead by Scale Venture Partners, and joined by return backers Sutter Hill Ventures and Pequot Ventures.
Variation Biotechnologies (Ottawa, Canada) a maker of vaccines for infectious diseases, has raised US$35.7M in Series A funding. The deal was lead by Clarus Ventures with participation from Arch Venture Partners and 5AM Ventures.
SunTen Phytotech (Taipei, Taiwan) a botanical drug development company, has raised $10M in Series B funding led by PacLink Capital, Taiwan Global Biofund Venture and 3V SourceOne Venture Capital.
Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised another $11.2M in Series B funding. Participants include Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures, Triathlon Medical Ventures and Guidant Compass Group.
Conatus Pharmaceuticals (San Diego, CA) a drug developer focused on liver disease, has secured $6.62 million of a $27.37M Series A round. Participants include Aberdare Ventures, Bay City Capital, Advent International and Hale BioPharma Ventures.
____________________
posted by Nico at
11:39 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home